Norwegian version of this page

Drug screening

The main aim of this work package is to establish a pipeline for cancer drug sensitivity screening of pancreatic cancer based on patient-derived xenografts and organoids.

We will develop:

  • 3D patient-derived organoids
  • assemble a custom library for drug screening of pancreatic cancer
  • screen samples
  • correlate drug sensitivity data with –omics and morphological tumour features (WP4 and 6).

Pancreatic ductal adenocarcinoma organoids are ex-vivo models of PC that can be established from very small biopsies, enabling the study of localised, advanced, and metastatic disease.

In order to obtain an overview of drug responses, we will use a set of established PDX models based on patient cells with tumour take that can be expanded in animals and screen against our library of cancer drugs. We will use the data from this screen and our overview of clinically used drugs to assemble a small custom library for further screening.

Given the limited amount of primary patient material, we will set up 3D organoids and establish a CDSS pipeline tailored to PC. Approximately 10 3D organoids will be obtained from fresh tissue samples for this purpose. Subsequently, 20 to 30 samples will be used to obtain CDSS data, correlate with findings in WP4, and validate against clinical response data to see whether this method can predict therapy responses.

Ultimately, we want to be able to routinely assist in treatment decision making in the clinic by identifying drug combinations that have higher efficiency than currently available treatment options for each individual patient.


  • Elin H. Kure (work package «Molecular characterization of tumour tissue and liquid biopsies»), OUH
  • Knut Jørgen Labori (work package «Surgery»), OUH/UiO
  • Caroline Verbeke (work package «Pathology»), UiO/OUH
  • Stein Kaasa and Olav Dajani (work package «Oncology»), OUH/UiO
  • Ivar Gladhaug (work package “Metabolomics”)
  • Tero Aittokallio (Computational medicine), OUH/UiO
Published Mar. 1, 2021 3:56 PM - Last modified Mar. 16, 2021 5:05 PM